Maze Therapeutics
secret to health
Maze Corporate Presentation May 2022
view our pipeline pipeline

latest press releases

February 24, 2022
Maze Therapeutics Announces Publication in Nature Describing a Novel Mechanism Linking Well-Established Genetic Drivers of ALS and FTD
February 17, 2022
Maze Therapeutics Announces Phase 1 Trial Initiation Evaluating MZE001 as a Potential Oral Treatment for Pompe Disease
February 10, 2022
Maze Therapeutics Presents New Preclinical Data Supporting Advancement of MZE001 as a Potential Treatment for Pompe Disease

latest media coverage

June 29, 2022
LifeSci 2nd Annual Genetic Medicines Symposium 2022
March 23, 2021
Exclusive: Maze unveils their $191M pipeline, taking on Vertex and two long-sought conditions
December 7, 2020
Maze Allies With BridgeBio and Alloy to Create 2 Biotechs
December 7, 2020
Endpoints News: Maze Therapeutics Spins Out Two New Companies with Alloy and BridgeBio
January 6, 2020
Top Life Sciences Startups to Watch in 2020
February 28, 2019
Forbes: Third Rock And ARCH-Backed Genetics Startup Launches With Nearly $200 Million
February 28, 2019
Xconomy: With $191M Haul, Maze Therapeutics Takes Aim at Genetic Diseases
February 28, 2019
MIT Technology Review: The secret to a new drug could be hiding in your genes

want to get a hold of a representative?

Jillian Connell
Maze Therapeutics
jconnell@mazetx.com

media inquires

Katie Engleman
1AB
katie@1abmedia.com

Contact Us